As discussed by Serizawa [1], results also showed that FGFR3 mutation in bladder cancer when combined with methylation markers (APC, RASSF1A and SFRP2) provided a sensitivity of 90% to identify bladder tumors. This evidence concerns the gene APC and urinary bladder cancer.